NCT02273154

Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Si Tianmei · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a Multicenter, open lable, parallel randomized controlled clinical trial. This study aimed to evaluate the treatment onset time, efficacy and safety in patients with major depressive disorders , accompanying anxiety receiving Buspirone and Paroxetine.

Conditions

• Major Depression Disorder

Interventions

Type	Name	Description
DRUG	Buspirone	MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
DRUG	Paroxetine	MDD patients with anxiety disorder take paroxetine (20-60mg/d)

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2014-10-23
• Last updated: 2014-10-23

Locations

6 sites across 1 country: China